Clinical Trial Update: Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation [Phase 3]

View source ↗

Summary

Phase 3 long-term safety update of lumacaftor/ivacaftor in cystic fibrosis patients who were 12 to less than 24 months old at treatment initiation and homozygou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19